Jin-Ku Lee

Jin-Ku Lee

Auto-generated profile, based on publicly available information

Jin-Ku Lee

Department of Anatomy and Cell Biology, Seoul National University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2017 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JLJin-Ku Lee
Jin-Ku Lee
JWJiguang Wang
Jiguang Wang
JSJason K. Sa
Jason K. Sa
ELErik Ladewig
Erik Ladewig
HLHae-Ock Lee
Hae-Ock Lee
DNDo-Hyun Nam
Do-Hyun Nam

27 September 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JLJin-Ku Lee
Jin-Ku Lee
ZLZhaoqi Liu
Zhaoqi Liu
JSJason K. Sa
Jason K. Sa
SSSang Shin
Sang Shin
JWJiguang Wang
Jiguang Wang
DNDo-Hyun Nam
Do-Hyun Nam

7 March 2023 in Biomaterials
Verified
Journal Article
Closed access
HJHye Ryeong Jun
Hye Ryeong Jun
HKHyun Ju Kang
Hyun Ju Kang
SJSung Hun Ju
Sung Hun Ju
JKJung Eun Kim
Jung Eun Kim
SJSang Youl Jeon
Sang Youl Jeon
DLDong Woo Lee
Dong Woo Lee

19 February 2024 in Molecular Therapy Oncology
Verified
Journal Article
Open access
JYJong Hyeon Yoon
Jong Hyeon Yoon
HYHan-Na Yoon
Han-Na Yoon
HKHyun Ju Kang
Hyun Ju Kang
HYHyejin Yoo
Hyejin Yoo
MCMoon Jung Choi
Moon Jung Choi
MJMihue Jang
Mihue Jang
Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells are a promising immunotherapy for solid cancers; however, their effectiveness against pancreatic cancer is limited by the immunosuppressive tumor microenvironment. In particular, low NK cell infiltration poses a major obstacle that reduces cytotoxicity. The current study aimed to enhance the tumor-homing capacity of CAR-NK cells by targeting the chemokine-chemokine receptor axis between NK and pancreatic cancer cells. To this end, data from a chemokine array and The Cancer Genome Atlas pan-cancer cohort were analyzed. Pancreatic cancer cells were found to secrete high levels of ligands for C-X-C motif receptor 1 (CXCR1) and CXCR2. Subsequently, we generated anti-mesothelin CAR-NK cells incorporating CXCR1 or CXCR2 and evaluated their tumor-killing abilities in 2D cancer cell co-culture and 3D tumor-mimetic organoid models. CAR-NK cells engineered with CXCR2 demonstrated enhanced tumor killing and strong infiltration of tumor sites. Collectively, these findings highlight the potential of CXCR2-augmented CAR-NK cells as a clinically relevant modality for effective pancreatic cancer treatment. By improving their infiltration and tumor-killing capabilities, these CXCR2-augmented CAR-NK cells have the potential to overcome the challenges posed by the immunosuppressive tumor microenvironment, providing improved therapeutic outcomes.

26 November 2019 in Genome Biology
Verified
Journal Article
Open access
JSJason K. Sa
Jason K. Sa
JHJae Ryoung Hwang
Jae Ryoung Hwang
YCYoung-Jae Cho
Young-Jae Cho
JRJi-Yoon Ryu
Ji-Yoon Ryu
JCJung-Joo Choi
Jung-Joo Choi
JLJeong-Won Lee
Jeong-Won Lee
Background: Gynecologic malignancy is one of the leading causes of mortality in female adults worldwide. Comprehensive genomic analysis has revealed a list of molecular aberrations that are essential to tumorigenesis, progression, and metastasis of gynecologic tumors. However, targeting such alterations has frequently led to treatment failures due to underlying genomic complexity and simultaneous activation of various tumor cell survival pathway molecules. A compilation of molecular characterization of tumors with pharmacological drug response is the next step toward clinical application of patient-tailored treatment regimens. Results: Toward this goal, we establish a library of 139 gynecologic tumors including epithelial ovarian cancers (EOCs), cervical, endometrial tumors, and uterine sarcomas that are genomically and/or pharmacologically annotated and explore dynamic pharmacogenomic associations against 37 molecularly targeted drugs. We discover lineage-specific drug sensitivities based on subcategorization of gynecologic tumors and identify TP53 mutation as a molecular determinant that elicits therapeutic response to poly (ADP-Ribose) polymerase (PARP) inhibitor. We further identify transcriptome expression of inhibitor of DNA biding 2 (ID2) as a potential predictive biomarker for treatment response to olaparib. Conclusions: Together, our results demonstrate the potential utility of rapid drug screening combined with genomic profiling for precision treatment of gynecologic cancers.

18 September 2022 in Advanced Biology
Verified
Journal Article
Closed access
JLJae Jun Lee
Jae Jun Lee
HKHyun Ju Kang
Hyun Ju Kang
SKStephanie S. Kim
Stephanie S. Kim
CCClémentine Charton
Clémentine Charton
JKJinho Kim
Jinho Kim
JLJin‐Ku Lee
Jin‐Ku Lee